Conversation with The Cancer LetterFree Agios’s Schenkein: “It’s not one disease. Just like lung cancer’s not one disease” July 27, 2018Vol.44 No.30By Paul Goldberg
Conversation with The Cancer LetterFree OSU’s Byrd: “It’s becoming necessary to consult with an expert, because it is complicated, and things are moving” July 27, 2018Vol.44 No.30By Paul Goldberg
Conversation with The Cancer Letter Maha Hussain: OS isn’t a practical endpoint in the context where patients are likely to live 10 years or more July 20, 2018Vol.44 No.29By Paul Goldberg
Conversation with The Cancer Letter Julia Beaver: SPARTAN and PROSPER showed MFS improvements greater than 20 months July 20, 2018Vol.44 No.29By Paul Goldberg
FDA spells out rules for new endpoint: Metastasis-free survival July 20, 2018Vol.44 No.29By Paul Goldberg
Conversation with The Cancer Letter Novartis’s Hirawat: “It’s a continuous dialogue that goes on on a daily basis” July 20, 2018Vol.44 No.29By Paul Goldberg
Pilot programs aim to revamp cancer drug approval process—from completion of trial to ODAC presentation July 20, 2018Vol.44 No.29By Paul Goldberg
FreeObituary Marlene McCarthy, formidable Breast Cancer Coalition advocate, dies at 74 July 20, 2018Vol.44 No.29By Frances M. Visco
